High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: Frequency and impact on clinical outcome

Leukemia

Volumn 28, Issue 7, 2014, Pages 1449-1458

  Krauth, M T ^a,b   Eder, C ^a   Alpermann, T ^a   Bacher, U ^a   Nadarajah, N ^a   Kern, W ^a   Haferlach, C ^a   Haferlach, T ^a   Schnittger, S ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

acute myeloid leukemia; ASXL1 mutation; KIT mutation; prognosis; secondary mutations; t(8; 21) RUNX1 RUNX1T1

Indexed keywords

ASXL1 PROTEIN; CBL PROTEIN; CD135 ANTIGEN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; KIT PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NRAS PROTEIN; NUCLEOPHOSMIN; PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 21; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME DELETION 9Q; CORRELATIONAL STUDY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METAPHASE; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX CHROMOSOME; SURVIVAL RATE; TRISOMY 8; X CHROMOSOME; Y CHROMOSOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84904040673     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.4     Document Type: Article

References (49)

1. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010 116 354-365.
2. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002 99 15-23.
3. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002 2 502-513.
4. Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, Haferlach T et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(821)/AML1-ETO. Br J Haematol 2006 134 616-619.
5. Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001 98 10398-10403.
6. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(821) acute myeloid leukemia. Cancer Cell 2002 1 63-74.
7. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002 100 59-66.
8. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005 115 2159-2168.
9. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukemias. Blood 2000 95 726-727.
10. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. AML1-ETO and C-KIT mutation/overexpression in t(821) leukemia implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005 102 1104-1109.
11. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006 107 1791-1799.
12. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(1616) a study of the German-Austrian AML Study Group (AMLSG). Blood 2013 121 170-177.
13. Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005 106 2113-2119.
14. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999 93 3074-3080.
15. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006 20 965-970.
16. Schlenk R. Dasatinib (Sprycelt) in patients with newly diagnosed core binding factor (CBF) acute myeloid leukemia (AML). ClinicalTrials gov 2013, NCT00850382.
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 33 451-458.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985 103 620-625.
19. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006 24 2480-2489.
20. Bü chner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J et al. Acute myeloid leukemia (AML) different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012 30 3604-3610.
21. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman J, Porwit A et al. Acute myeloid leukemia with recurrent genetic abnormalities. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Lyon, France, 2008, pp 110-123.
22. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia a study on 350 cases. Leukemia 2002 16 53-59.
23. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007 46 494-499.
24. Shaffer LG, Tommerup N. ISCN 2013 An International System for Human Cytogenetic Nomenclature. Karger Basel, Switzerland and New York, NY, USA, 2013.
25. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004 104 3078-3085.
26. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010 23 379-390.
27. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA\+, AML1-ETO\+, or CBFBMYH11\+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003 102 2746-2755.
28. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013 27 82-91.
29. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML the combination matters-an analysis of 3082 patients. Blood 2008 111 2527-2537.
30. Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005 105 3319-3321.
31. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009 114 2220-2231.
32. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 106 3733-3739.
33. Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005 90 881-889.
34. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010 116 5486-5496.
35. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML a study of 2502 patients. Blood 2006 107 3847-3853.
36. Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders an analysis of 636 cases. Haematologica 2012 97 1890-1894.
37. Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain D620E and E627E. Leukemia 2006 20 2195-2197.
38. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003 21 4642-4649.
39. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. International Agency for Research on Cancer (IARC) Lyon, France, 2008.
40. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011 108 2450-2455.
41. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(821) a Cancer and Leukemia Group B Study. J Clin Oncol 2006 24 3904-3911.
42. Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013 92 163-171.
43. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004 22 3741-3750.
44. Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R et al. Therapy-related acute myeloid leukemia with t(821) (q22q22) shares many features with de novo acute myeloid leukemia with t(821)(q22q22) but does not have a favorable outcome. Am J Clin Pathol 2009 131 647-655.
45. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011 117 2137-2145.
46. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse results of the UK MRC AML 10 trial. Br J Haematol 2002 118 385-400.
47. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1) an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003 102 1232-1240.
48. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A et al. A white blood cell index as the main prognostic factor in t(821) acute myeloid leukemia (AML) a survey of 161 cases from the French AML Intergroup. Blood 2002 99 3517-3523.
49. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F et al. Prognosis of inv(16)/t(1616) acute myeloid leukemia (AML) a survey of 110 cases from the French AML Intergroup. Blood 2003 102 462-469.